Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Henock G Yebyo"'
Autor:
Gerezgiher B Abera, Henock G Yebyo, Haftamu Hailekiros, Selam Niguse, Yibrah Berhe, Goitom Gigar, Tsehaye Asmelash, Gelila Goba
Publikováno v:
PLoS ONE, Vol 18, Iss 1, p e0280191 (2023)
BackgroundCervical cancer is a preventable disease if treated early, but remains the second leading cause of cancer-related mortality among women in low and middle-income countries. Data on epidemiology and risk factors in these settings are scarce.
Externí odkaz:
https://doaj.org/article/9dc5877d00b64144a1cfaec12b471d3c
Autor:
Michaela C Barbier, Yuki Tomonaga, Dominik Menges, Henock G Yebyo, Sarah R Haile, Milo A Puhan, Matthias Schwenkglenks
Publikováno v:
PLoS ONE, Vol 17, Iss 11, p e0277282 (2022)
BackgroundIn metastatic hormone-sensitive prostate cancer (mHSPC) treatment, survival benefits have been shown by adding docetaxel or recent androgen receptor axis-targeted therapies (ARATs) abiraterone, apalutamide, or enzalutamide to androgen depri
Externí odkaz:
https://doaj.org/article/95228d3593c848d08f1aab9ad6994784
Publikováno v:
BMC Cardiovascular Disorders, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background We previously showed that the 10-year cardiovascular disease (CVD) risk threshold to initiate statins for primary prevention depends on the baseline CVD risk, age, sex, and the incidence of statin-related harm outcome and competin
Externí odkaz:
https://doaj.org/article/51eaac92992f4bfd80b2791c30d35527
Autor:
Dominik Menges, Henock G. Yebyo, Sergio Sivec-Muniz, Sarah R. Haile, Michaela C. Barbier, Yuki Tomonaga, Matthias Schwenkglenks, Milo A. Puhan
Publikováno v:
European Urology Oncology. 5:605-616
Multiple treatments for metastatic, hormone-sensitive prostate cancer (mHSPC) are available, but their effects on health-related quality of life (HRQoL) and benefit-harm balance remain unclear.To assess clinical effectiveness regarding survival and H
Publikováno v:
BMC Cardiovascular Disorders, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background Patient preferences are key parameters to evaluate benefit-harm balance of statins for primary prevention but they are not readily available to guideline developers and decision makers. Our study aimed to elicit patient preference
Externí odkaz:
https://doaj.org/article/f077e92e49d2462882089d2ec68f63c4
Publikováno v:
Therapeutic Advances in Chronic Disease, Vol 10 (2019)
Background: We determined the risk thresholds above which statin use would be more likely to provide a net benefit for people over the age of 75 years without history of cardiovascular disease (CVD). Methods: An exponential model was used to estimate
Externí odkaz:
https://doaj.org/article/7ad51a813e2147ec897be1a7373471fd
Autor:
Henock G. Yebyo, Huldrych F. Günthard, Eva A. Rehfuess, Nicola Serra, Sarah R. Haile, Oliver Senn, Gregory M. Lucas, Oliver Langselius, Jennifer E. Thorne, Milo A. Puhan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db8647b4b81f3544abf2410fd7d14613
https://doi.org/10.2139/ssrn.4427462
https://doi.org/10.2139/ssrn.4427462
Autor:
Michaela C. Barbier, Yuki Tomonaga, Dominik Menges, Henock G. Yebyo, Sarah R. Haile, Milo A. Puhan, Matthias Schwenkglenks
Background In metastatic hormone-sensitive prostate cancer (mHSPC) treatment, survival benefits have been shown by adding docetaxel or recent androgen receptor axis-targeted therapies (ARATs) abiraterone, apalutamide, or enzalutamide to androgen depr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b05e49252bca9695ca66e39c0e24be4
https://www.zora.uzh.ch/id/eprint/226005/
https://www.zora.uzh.ch/id/eprint/226005/
Autor:
Frances M. Wang, Henock G. Yebyo, Shoshana H. Ballew, Miguel Cainzos-Achirica, Cynthia Boyd, Milo A. Puhan, Kunihiro Matsushita, Michael J. Blaha, Nancy L. Schoenborn
Publikováno v:
American Journal of Preventive Cardiology. 13:100468
Autor:
Frances M Wang, Henock G Yebyo, Cynthia Boyd, Milo A Puhan, Kuni Matsushita, Michael J Blaha, Nancy Schoenborn
Publikováno v:
Circulation. 145
Background: Personalized cardiovascular disease (CVD) preventive therapy for older adults is important and emphasized in current clinical guidelines. Older adults often have multiple chronic conditions, are at higher risk for medication side effects,